Urolon Company

Rethinking stress incontinence treatment with Urolon®, an innovative bioresorbable urethral injectable as a first choice, minimally invasive treatment after pelvic floor muscle therapy. Urolon® bridges the gap between conservative and surgical interventions. CE certified since 2018, available in 12 countries.
Industry: Pelvic & Uterine Healthcare
Headquarters: Utrecht, The Netherlands
Founded Date: 03-01-2014
Employees Number: 1-10
Funding Status: Self-funded
Total Funding: $6,000,000
Estimated Revenue: Less than $1M

Visit Website
Register and Claim Ownership